Jakubowitz Law
(212) 867-4490
Business Minds. Legal Insight.

We combine large firm expertise with small firm attention. Our clients can expect the best results and the most personal experience.

Jakubowitz Law IS HERE TO HELP SHAREHOLDERS WHO PURCHASED BioMarin Pharmaceutical Inc. (BMRN)

BioMarin is facing a class action lawsuit alleging that the Company made materially false and/or misleading statements and/or failed to disclose that: (i) differences between the Phase 1/2 and Phase 3 study of valoctocogene roxaparvovec, an investigational adenoassociated virus gene therapy, limited the reliability of the Phase 1/2 study to support valoctocogene roxaparvovec’s durability of effect; (ii) as a result, it was foreseeable that the U.S. Food and Drug Administration would not approve the Biologics License Application for valoctocogene roxaparvovec without additional data; and (iii) as a result, the Company’s public statements were materially false and misleading at all relevant times.

If you incurred a loss on BMRN stocks purchased between February 28, 2020 and August 18, 2020, this lawsuit is on your behalf. The lawsuit was filed in the the United States District Court for the Northern District of California, and our firm is reaching out to investors to discuss their legal rights.

If you wish to act as a representative of the shareholders harmed by this misconduct, you may ask the court to appoint you as lead plaintiff. A lead plaintiff directs the litigation and participates in important decisions, including whether to accept a settlement for the class in the action.

You only have until November 24, 2020 to apply to be lead plaintiff. The court will then evaluate the applicants and choose a lead plaintiff. You are not required to act as a lead plaintiff in order to participate in any recovery.

Fill out the form below to be contacted by a representative of Jakubowitz Law.

Loss Submission Form

See If you Qualify for Monetary Reward

Jakubowitz Law does not share your information with others.
There is no cost or obligation for you to submit

This submission does not create an attorney-client relationship.
If we believe that you might be an appropriate lead plaintiff, we will contact you to discuss
whether to establish an attorney-client relationship.